ストックスクリーナーアプリを入手
25.51
1.71%
0.43
プレマーケット:
26.48
0.97
+3.80%
Hemab Therapeutics Holdings Inc (COAG) 最新ニュース
Hemab soars 89% on debut as biopharma IPOs stay strong in May - BioWorld News
Hemab Therapeutics Holdings, Inc.Common Stock (COAG) Stock Price, News, Quote & History - FinancialContent
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans - Yahoo Finance
Jefferies Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Maintains Target Price $39 - Moomoo
SEPN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
MRVI Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
COAG: Lead asset moves to phase III, with robust pipeline and funding secured through 2029 - TradingView
Top Hemab Therapeutics (COAG) Competitors 2026 - MarketBeat
Hemab Therapeutics Pulls Back After 53% IPO Surge - Bez Kabli
Novo Holdings portfolio company Hemab Therapeutics completes successful Nasdaq IPO - Novo Holdings
Hemab Therapeutics Hldgs (COAG) Stock Analysis Report | Financials & Insights - Benzinga
Hemab Therapeutics (COAG) Stock Forecast and Price Target 2026 - MarketBeat
Hemab Therapeutics (COAG) Stock Trends and Sentiment 2026 - MarketBeat
Hemab Therapeutics (COAG) Earnings Date and Reports 2026 - MarketBeat
COAG Technical Analysis & ETF Price Forecast - Intellectia AI
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference - The Manila Times
Latest COAG ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
AI Investing InsightsOfficial HomepageIntellectia AI™ - Intellectia AI
Hemab Therapeutics Hldgs Initiated at Outperform by Evercore ISI Group - Moomoo
COAG Initiates Coverage By Evercore ISI Group -- Rating Upgraded to Outperform - GuruFocus
COAG Initiates Coverage by Goldman Sachs -- Price Target Announced at $36 - GuruFocus
Wedbush Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $42 - Moomoo
Hemab Therapeutics Hldgs Initiated at Buy by Jefferies - Moomoo
Hemab Therapeutics Hldgs Price Target Announced at $50.00/Share by Evercore ISI Group - Moomoo
Jefferies Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $39 - Moomoo
Evercore Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $50 - Moomoo
This Avalyn Pharma Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Goldman Sachs Initiates Coverage on Hemab Therapeutics With Buy Rating, $36 Price Target - marketscreener.com
Goldman Sachs Initiates Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Announces Target Price $36 - Moomoo
Goldman Sachs initiates Hemab Therapeutics stock with buy rating on rare disease drug potential - Investing.com
ETFs Investing in Hemab Therapeutics Holdings, Inc. Stocks - TradingView
COAG Technical Analysis | Trend, Signals & Chart Patterns | HEMAB THERAPEUTICS HOLDINGS (NASDAQ:COAG) - ChartMill
Earnings Scheduled For May 21, 2026 - Sahm
Novo-backed biotech Hemab raises $301.5 million in upsized IPO - MSN
COAG SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
Hemab Therapeutics Holdings, Inc. Q1 2026: Net loss $(22.7)M, EPS $(23.98) — 10-Q Summary - TradingView
Hemab Therapeutics Reports Q1 2026 Financial Results, Completes $346.7M IPO and Advances Breakthrough Therapy Sutacimig for Rare Bleeding Disorders - Minichart
Earnings Flash (COAG) Hemab Therapeutics Posts Q1 Net Loss $23.98 a Share - marketscreener.com
Hemab Therapeutics reports Q1 2026 net loss $22.7M, cash $163.5M; completed $346.7M IPO - TradingView
COAG: IPO raised $346.7M, advancing late-stage trials for rare bleeding disorder therapies - TradingView
Hemab Therapeutics (COAG) Q1 2026 loss, $346.7M IPO and FDA breakthrough nod - Stock Titan
FDA grants Hemab breakthrough tag on rare bleed drug as $346.7M IPO closes - Stock Titan
Hemab Therapeutics Holdings, Inc. Common Stock (COAG) AI-Powered Stock Analysis - Meyka
Why Is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Up Today? - Meyka
Why Is Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Down Today? - Meyka
Seaport, Hemab price upsized IPOs, eyeing $550M in proceeds - MSN
COAG SEC FilingsHEMAB THERAPEUTICS HOLDINGS 10-K, 10-Q, 8-K Forms - Stock Titan
Hemab Therapeutics Holdings Earnings Date, Reports & Earnings Call - Moomoo
1.27%
1.43%
大文字化:
|
ボリューム (24 時間):